67 results about "Antibacterial protein" patented technology

The invention discloses a marine bacteriophage antibacterial lysin prediction method, device, medium and equipment, and relates to the field of biological medicine and computational biology. Comprising the following steps: constructing a training data set based on a globally known antibacterial protein sequence; and training a protein sequence classification model based on deep learning by using the antibacterial protein data set to obtain a marine antibacterial lysin prediction model. The method comprises the following steps: carrying out data standardization processing on a to-be-predicted bacteriophage protein sequence, inputting the to-be-predicted bacteriophage protein sequence into a protein language model, carrying out self-attention modeling on the input sequence through a ProtT5 module, and extracting global structure and function related features to obtain a first feature vector; extracting a short sequence local dependency feature through a ProtBERT module to obtain a second feature vector; performing weighted summation on the first feature vector and the second feature vector to generate a fusion feature vector; and carrying out probability prediction on the fusion feature vector, and outputting the antibacterial tag and the prediction confidence of the marine phage sequence to be predicted.

The invention discloses production and application of an antibacterial protein targeting enterococcus pluvialis. Specifically, the antibacterial protein comprises an amino acid sequence as shown in any one of SEQ ID NO.15-28 or an active fragment and an analogue of the amino acid sequence. According to the present invention, the potential antibacterial protein is found from the genome of the bacteria or the bacteriophage, and the antibacterial protein can inhibit the enterococcus pluvialis in the targeting manner; the antibacterial protein with biological activity can be obtained in a heterologous expression mode and can remove the enterococcus pluvialis in a targeted mode, and then related diseases caused by the enterococcus pluvialis are relieved and treated. The antibacterial protein provided by the invention can perform targeted sterilization without damaging normal human symbiotic flora, and can avoid side effects caused by traditional antibiotic treatment.

The invention provides an antibacterial protein targeting chicken enterococcus as well as a preparation method and application of the antibacterial protein. Specifically, the invention provides an antibacterial protein targeting chicken enterococcus or a chimeric compound thereof, and the antibacterial protein comprises one or more of proteins formed by the following amino acid sequences: (a) an amino acid sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 9; (b) a derivative sequence which is obtained by replacing, adding and / or deleting one or more amino acids from the amino acid sequence of (a) and has the same function as (a); and (c) a derived amino acid sequence of which the identity with any one sequence from SEQ ID NO: 1 to SEQ ID NO: 9 is 85% or more or 90% or more. The antibacterial protein disclosed by the invention can be used for efficiently killing chicken enterococcus and has specificity.

The invention belongs to the technical field of biology, and particularly discloses a high-temperature-resistant antibacterial protein Cystatin B sourced from marine fish as well as a preparation method and application of the high-temperature-resistant antibacterial protein Cystatin B. The high-temperature-resistant antibacterial protein Cystatin B is derived from pomfret, and the amino acid sequence of the high-temperature-resistant antibacterial protein Cystatin B is as shown in SEQ ID NO. 1; the nucleotide sequence of the gene for coding the high-temperature-resistant antibacterial protein Cystatin B is as shown in SEQ ID NO.2, and the sequences of primers adopted for cloning the gene are as shown in SEQ ID NO.3-4. The high-temperature-resistant antibacterial protein Cystatin B has a remarkable antibacterial effect on gram-negative bacteria such as escherichia coli, vibrio parahaemolyticus and edwardsiella tarda as well as gram-positive bacteria such as staphylococcus aureus; and after being treated at the temperature of 100 DEG C, the antibacterial agent still can keep relatively high antibacterial activity. The antibacterial protein is simple in preparation method, can replace traditional antibiotics, and can quickly and efficiently prevent and treat various common bacterial diseases in aquaculture.

The invention belongs to the technical field of laundry detergents, and particularly relates to an HPV sterilization underwear laundry detergent containing lysozyme-antibacterial protease and a preparation process. The HPV sterilization underwear laundry detergent containing lysozyme-antibacterial protease comprises the following components in percentage by mass: 12%-18% of modified alkyl glycoside, 4%-6% of an auxiliary surfactant, 1.5%-3% of a lysozyme-antibacterial protease compound, 0.8%-1.5% of double-chain quaternary ammonium salt, 2%-3% of sodium citrate, 1%-2% of glycerol, 1%-1.5% of citric acid, 0.1%-0.2% of a preservative, 0.1%-0.3% of essence and the balance of deionized water. The laundry detergent disclosed by the invention is mild in effect, short in decontamination time and good in decontamination effect, especially has an excellent decontamination effect on protein and sebum, and is especially suitable for decontaminating underwear.

The present invention relates to an antibacterial protein SBL200 having a bacteriolytic activity specific to Streptococci, and a method for preparing the antibacterial protein SBL200 having a bacteriolytic activity specific to Streptococci. More particularly, the present invention relates to: an antibacterial protein SBL200 specific for streptococcus, which is characterized by having an ability to specifically lyse streptococcus and having an amino acid sequence represented by SEQ ID NO: 1; and a composition for treating infection induced by streptococcus, which contains the antibacterial protein SBL200 specific for streptococcus as an active ingredient .

The present invention relates to an antimicrobial protein SBL2200 having antimicrobial activity specific for Streptococci and, more specifically, to: a Streptococci-specific antimicrobial protein SBL2200 having the capacity to specifically lyse Streptococci and having an amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for the treatment of infections caused by Streptococci, comprising the Streptococci-specific antimicrobial protein SBL2200 as an active ingredient.

The invention relates to the field of natural products, in particular to active hawthorn protein for inhibiting a bacterial biofilm and a preparation method and application of the active hawthorn protein for inhibiting the bacterial biofilm, and the active hawthorn protein for inhibiting the bacterial biofilm comprises antibacterial hawthorn protein and a multi-element modification layer compounded with the antibacterial hawthorn protein; the modification layer is obtained by compounding polysaccharide and amine components. The antibacterial protein is extracted from hawthorn fruits, and the surface of the antibacterial protein is subjected to surface modification through polysaccharides and natural amines, so that the purpose of improving the acid resistance of the hawthorn protein is achieved, and the antibacterial protein can stably act on a bacterial biofilm in an acidic microenvironment. Meanwhile, after surface modification, the affinity adhesion capacity of hawthorn protein and a biological membrane can be improved, and the interaction between a composite structure and a bacterial biological membrane structure is enhanced, so that the penetrating effect is achieved, and the antibacterial effect is improved.

The invention discloses application of an antibacterial agent and bacteriophage lyase. The bacteriophage lyase has a remarkable splitting effect on gram-negative bacteria, so that the bacteriophage lyase can be used as a broad-spectrum antibacterial protein. For example, the antibacterial effect on gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa and klebsiella pneumoniae is remarkable. The antibacterial protein has relatively high temperature tolerance and pH tolerance, can replace antibiotics, and is applied to prevention and treatment of bacterial diseases as an external medicine or an internal medicine and sterilization of medical instruments and medical places; and the product can also be used as an additive to be applied to the fields of feed processing, food industry, animal husbandry, beer industry, aquaculture, cosmetic production, fruit preservation and the like.

The present invention discloses a strain of Bacillus Velez CB6 and the antimicrobial protein produced and its application, belonging to the field of microbial application technology. The deposit number of the Bacillus Velez CB6 is CGMCC NO.30515. The strain has a good antagonistic effect on Gram-negative bacteria such as multidrug-resistant Escherichia coli. The antimicrobial protein CB6-E prepared by fermentation of the strain shows good antimicrobial activity against a variety of Gram-negative bacteria, and has good safety for a variety of animals. CB6-E has a good therapeutic effect on mice and wax moths infected with polymyxin-resistant and carbapenem-resistant Escherichia coli. The antimicrobial protein CB6-E prepared by fermentation of Bacillus Velez CB6 of the present invention is expected to enrich the current existing antimicrobial drug library and provide new hope for the treatment of multidrug-resistant Gram-negative bacterial infections.

The invention discloses a bacillus amyloliquefaciens BS-3 and an antibacterial protein and application derived therefrom, belonging to the technical field of microorganisms and genetic engineering. The invention discloses a bacillus amyloliquefaciens BS-3, and the deposit number is CCTCC NO: M 2024893. The antibacterial protein derived from Bacillus amyloliquefaciens BS-3, and its amino acid sequence is shown in SEQ ID NO.7. Bacillus amyloliquefaciens BS-3 can inhibit Colletotrichum oxysporum, Alternaria rubber, Pseudomonas microsporus, Phytophthora litchii, Phytophthora cucurbitae, Phytophthora capsici, and Citrus black spot pathogen. The antibacterial protein derived from Bacillus amyloliquefaciens BS-3 can inhibit Colletotrichum oxysporum, Alternaria rubber, and Pseudomonas microsporus.

The present invention provides a polypeptide as defined by one of the following (i) to (iii), and an antibacterial protein, an antibacterial agent, a disinfectant, a pharmaceutical composition, an antibacterial agent composition, and a disinfectant composition each comprising the following polypeptide: (i) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1; (ii) a polypeptide comprising an amino acid sequence obtained by deleting, substituting, inserting and / or adding one or more amino acid residues in the amino acid sequence as shown in SEQ ID NO: 1; or (iii) a polypeptide comprising an amino acid sequence having 80% or higher sequence identity with the amino acid sequence as shown in SEQ ID NO: 1.

The application discloses a marine bacteriophage antibacterial lysin prediction method and device, medium and equipment, and relates to the fields of biological medicine and computational biology. The method comprises the following steps: constructing a training data set based on global known antibacterial protein sequences; training a protein sequence classification model based on deep learning by using the antibacterial protein data set to obtain a marine antibacterial lysin prediction model. After data standardization processing, the protein sequence of the bacteriophage to be predicted is input into the protein language model, the input sequence is subjected to self-attention modeling by a ProtT5 module, global structure and function related features are extracted, and a first feature vector is obtained; short sequence local dependency features are extracted by a ProtBERT module, and a second feature vector is obtained; the first and second feature vectors are weighted and summed to generate a fusion feature vector; and the fusion feature vector is subjected to probability prediction, and an antibacterial label and a prediction confidence of the marine bacteriophage sequence to be predicted are output.

The invention provides antibacterial protein targeting clostridium scintillator as well as a preparation method and application of the antibacterial protein. Specifically, the invention provides an antibacterial protein targeting clostridium scintillator or a chimeric compound thereof, and the antibacterial protein comprises one or more of proteins formed by the following amino acid sequences: (a) an amino acid sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 13; (b) a derivative sequence which is obtained by replacing, adding and / or deleting one or more amino acids from the amino acid sequence of (a) and has the same function as (a); and (c) a derived amino acid sequence of which the identity with any one sequence from SEQ ID NO: 1 to SEQ ID NO: 13 is 85% or more or 90% or more. The antibacterial protein disclosed by the invention can be used for efficiently killing clostridium scintillation and has specificity.

The invention is applicable to the technical field of bioengineering, and provides a streptococcus suis bacteriophage antibacterial protein Lys8387 as well as a preparation method and application thereof, and the amino acid sequence of the streptococcus suis bacteriophage antibacterial protein Lys8387 is shown as SEQ ID NO.2. A novel bacteriophage antibacterial protein capable of playing splitting and depolymerizing double activities on streptococcus suis is constructed through a genetic engineering technology, and the lyase is novel in sequence, shows strong bactericidal activity on multi-drug-resistant streptococcus suis, can be independently used or compounded with other substances for use, or can be prepared into an enzyme preparation, and can be used for preparing an antibacterial agent for multiple drug-resistant streptococcus suis. The compound not only has bactericidal activity on streptococcus suis, but also has a degradation effect on capsular polysaccharide of streptococcus suis, K2 type klebsiella pneumoniae and the like, and a thought is provided for preparing a medicine for preventing and treating diseases caused by infection of microorganisms such as streptococcus suis and the like.

A method for preparing a drug for treating bovine cholecystitis belongs to the field of biological veterinary medicine. The present invention utilizes the original ecological pathogens of bovine cholecystitis, and further adds bovine blood, trace elements, and freeze-dried Escherichia coli powder, freeze-dried enterococcus powder, freeze-dried Pseudomonas aeruginosa powder, and lecithin. Weak ultrasound is used in a buffer solution to activate the activity of various pathogens, and in the intelligent cultivation process, the corresponding antimicrobial peptides and antimicrobial proteins are strongly induced in the body of the big-headed golden fly larvae. The antimicrobial peptides and antimicrobial proteins have the characteristics of high biological activity and broad spectrum of action. Clinical treatment results show that the drug prepared by the present invention has good efficacy and high efficiency. The production process of the present invention is easy to industrialize and control, the product consistency is good, energy is saved, and it is suitable for large-scale production.

The invention discloses antibacterial protein from bacillus amyloliquefaciens BS-3 and application of the antibacterial protein, and belongs to the technical field of microorganisms and genetic engineering. The invention discloses a bacteriostatic protein from bacillus amyloliquefaciens BS-3. The amino acid sequence of the bacteriostatic protein is as shown in SEQ ID NO. 7. The antibacterial protein from the bacillus amyloliquefaciens BS-3 can inhibit colletotrichum acutatum, alternaria rubra and pestalotiopsis microspora.

The invention discloses bacillus velezensis Jcl-10 and application of the bacillus velezensis Jcl-10 in prevention and treatment of vibrio cholerae. The strain Jcl-10 is preserved in the China Center for Type Culture Collection, the preservation time is January 25, 2024, and the preservation number is CCTCC N: M 2024212. The bacillus velezensis Jcl-10 disclosed by the invention is identified as a gram positive bacterium after being subjected to gram staining. The bacterial strain can produce antibacterial peptide substances, antibacterial protein substances, polyketide synthetase substances and the like with bacteriostatic action, and can be well applied to prevention and treatment of aquatic diseases caused by vibrio cholerae. The Jcl-10 is added into the aquatic feed, so that the morbidity of aquaculture animals can be effectively reduced, and the economic yield of the aquaculture animals can be increased. In conclusion, the bacillus velezensis Jcl-10 disclosed by the invention has outstanding performance in the prevention and treatment of vibrio cholerae, and provides a powerful guarantee for continuous and healthy culture of aquatic products.

The present invention relates to an antibacterial protein SBL2200 having a bacteriolytic activity specific to Streptococcus (S trept cocc i), and to a method for preparing the antibacterial protein SBL2200 having a bacteriolytic activity specific to Streptococcus (S trept cocc i). More particularly, the present invention relates to: an antibacterial protein SBL2200 specific for streptococcus, characterized by having an ability to specifically lyse streptococcus and having an amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for treating infection induced by streptococcus, containing the antibacterial protein SBL2200 specific for streptococcus as an active ingredient and a compound.

The present disclosure provides compositions and formulations comprising a mixture of antibacterial proteins, such as bacteriocins for the treatment of Klebsiella infections. The composition and formulations, as disclosed, comprises a mixture of klebicins (proteins or variants thereof) with broader target cell ranges in order to effectively treat Klebsiella infections. The present disclosure provides kits and methods for treating Klebsiella infections.

The present invention relates to nuclease bacteriocin-derived antimicrobial protein complexes, their preparation and use, and related products having antimicrobial surfaces. The complexes comprise a nuclease bacteriocin polypeptide and an immunity polypeptide linked to a bacteria-binding moiety.

Described is an antibacterial protein S2200 which has specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, described is antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus, which has the ability to specifically lyse Staphylococci including Staphylococcus aureus and has the amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for the treatment of infections caused by Staphylococci including Staphylococcus aureus, containing as an active ingredient antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus.

The invention discloses a lactobacillus plantarum bacteriostatic agent and application thereof, and relates to the technical field of microbial engineering. According to the lactobacillus plantarum LP2301 provided by the invention, fermentation liquor of the lactobacillus plantarum LP2301 can be used for effectively inhibiting aquatic pathogenic bacteria streptococcus agalactiae, limiting the growth of the streptococcus agalactiae, reducing the use of antibiotics, ensuring food safety and guaranteeing the health of animals and human beings by secreting metabolites such as bacteriostatic proteins and organic acids. Secondly, the invention provides an application of the lactobacillus plantarum bacteriostatic agent, and the lactobacillus plantarum LP2301 is compounded into the bacteriostatic agent; through multi-target cooperation of the cortex phellodendri extract and the rosmarinic acid, the antibacterial efficiency of single probiotics is remarkably optimized; active ingredients of cortex phellodendri directionally destroy a biological membrane barrier of streptococcus agalactiae and disintegrate an adhesion defense system of pathogenic bacteria; rosmarinic acid blocks a bacterial energy metabolism pathway synchronously, so that pathogens lose proliferative power; and exclusive bacteriocin secreted by the LP2301 accurately breaks down a cell membrane structure, so that fatal killing is realized.

An antibacterial protein against Bacillus with the amino acid sequence as set forth in SEQ ID NO: 1 is disclosed. Also disclosed is a method of preparing an antibacterial protein against Bacillus. The method includes: culturing BL21-pBAD-BAL200 cells, the BL21-pBAD-BAL200 cells including a plasmid that comprising a sequence as set forth in SEQ ID NO: 2; inducing the expression of the antibacterial protein; and purifying the antibacterial protein.

The invention relates to tomato SGT1 protein, application of the tomato SGT1 protein to prevention and treatment of tomato gray mold and a biological preparation for preventing and treating the tomato gray mold, and belongs to the technical field of tomato disease prevention and treatment. In order to solve the problems that the existing plant-source antibacterial protein is difficult to effectively inhibit botrytis cinerea infection and lags in action time, the invention provides application of the tomato SGT1 protein in prevention and treatment of botrytis cinerea, the amino acid sequence of the tomato SGT1 protein is shown as SEQ ID No: 1, and the tomato SGT1 protein can effectively inhibit the growth of botrytis cinerea hyphae, destroy the completeness of conidia of the botrytis cinerea and inhibit the growth of the botrytis cinerea hyphae. The botrytis cinerea can be effectively prevented and controlled, the infection capacity of botrytis cinerea on tomato leaves is remarkably reduced, the method belongs to typical early-stage infection inhibition, the prevention and control efficiency of the botrytis cinerea can be remarkably improved, 'early intervention and multi-target 'precise prevention and control of dead body nutritional pathogenic bacteria are realized, and an important basis is provided for developing a novel biological agent for preventing and controlling the botrytis cinerea.

The invention discloses preparation and application of a proteoglycan colloid material capable of rapidly stopping bleeding and promoting wound healing, and belongs to the field of biological materials. Basic amino acid rich in lysine or arginine is designed and expressed through molecular engineering, and then basic protein and hyaluronic acid with negative electricity are combined through a supramolecular assembly method to prepare a proteoglycan material with antibacterial ability. Then, recombinant mucoprotein rich in tyrosine is designed and expressed, and a DOPA adhesion group is formed through tyrosinase modification, so that the instant adhesion of the tissue adhesion material is enhanced. The amino acid of the basic protein remarkably enhances the interaction of various molecules of proteoglycan, meanwhile, the basic amino acid endows the tissue adhesive with excellent antibacterial ability, and the tissue adhesive provided by the invention has instant tissue adhesion performance, excellent biocompatibility and excellent antibacterial ability and hemostatic performance, and is suitable for being used in the field of medical instruments. The healing of different types of bleeding scenes and irregular wounds is facilitated.

The present invention relates to an antibacterial protein S2200 having an antibacterial activity specific to Staphylococcus aureus, including Staphylococcus aureus, and a method for preparing the antibacterial protein S2200, the antibacterial protein S2200 having an antibacterial activity specific to Staphylococcus aureus, the antibacterial protein S2200 having an antibacterial activity specific to Staphylococcus aureus, and the antibacterial protein S2200 having an antibacterial activity specific to Staphylococcus aureus. More particularly, the present invention relates to: an antibacterial protein S2200 specific to staphylococcus aureus including staphylococcus aureus, which is characterized by having an ability to specifically lyse the staphylococcus aureus including staphylococcus aureus and having an amino acid sequence represented by SEQ ID NO: 1; and a pair comprising the antibacterial protein S2200 as an active ingredient, said antibacterial protein S2200 being specific to staphylococcus aureus including staphylococcus aureus. The present invention relates to a pharmaceutical composition for treating infections induced by staphylococcus, including Staphylococcus aureus, of an antibacterial protein S2200 specific to staphylococcus, including Staphylococcus aureus.

The invention discloses a method for preparing antibacterial protein feed powder by using composite probiotics and puffed feathers. Step 1: Wash and dry the discarded feathers, process them with a twin-screw extruder, and then filter them through a filter screen to obtain uniform puffed feather powder; Step 2: Mix the prepared puffed feather powder with glucose, dissolve them in deionized water, sterilize them with ultra-high pressure, and prepare a fermentation medium; Step 3: Inoculate the activated composite bacterial liquid into the fermentation medium, place it in a shaking table for constant temperature fermentation and culture; Step 4: After the fermentation is completed, collect the fermentation products to obtain protein feed powder; the composite bacterial liquid is a composite bacterial liquid of Lactobacillus paracasei and Bacillus subtilis. The present invention utilizes Lactobacillus paracasei and Bacillus subtilis for synergistic fermentation, and the utilization rate of puffed feathers reaches 65%. It not only improves the palatability and nutritional value of puffed feather powder, but also increases the product added value of puffed feather powder.

This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5′ cap or a 3′ extension.

Described are antimicrobial proteins, a nucleic acid sequence encoding the said protein, a gene encoding the said protein or comprising the said nucleic acid sequence, a host cell comprising the said nucleic acid sequence or the said gene, a composition comprising the antimicrobial protein and the use of the antimicrobial protein or the composition as antiseptic agent.